Company Overview and News

5
AGTC / Applied Genetic Technologies Corp DEF 14A

2018-10-16 sec.gov - 4
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AGTC

7
Nightstar Therapeutics: Sell-Off Is A Great Entry Point For Long-Term Investors

2018-09-25 seekingalpha
At this weekend's EURETINA 2018, Nightstar Therapeutics presented promising data for its XIRIUS trial for the treatment of X-linked Retinitis Pigmentosa (XLRP).
WFC WFCNP AGTC NITE BIIB

1
AGTC / Applied Genetic Technologies Corp FORM 8-K (Current Report)

2018-09-24 sec.gov
Form 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AGTC

1
AGTC Appoints William Aliski to its Board of Directors

2018-09-24 globenewswire
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced it has appointed William Aliski to the company’s Board of Directors.
AGTC RARE

69
Top Analyst Upgrades and Downgrades: Abbott Labs, Avon, Caesars, Comcast, Rowan, UnitedHealth, Vonage and More

2018-09-24 247wallst - 3
Stocks have hit all-time highs, but they were indicated marginally lower on Monday after trade tariffs are set to kick in against China. Many investors have seen lower upside from buying on market pullbacks than in prior years, and now they have to consider how they want to have their investments positioned for the rest of 2018 and as 2019 approaches.
WFCNP TXRH EAT APD CCV UAA KRYS AVP DRI CCZ AMD ABT CMCSK ABT WFC AGTC RDC CMCSA NBEV UNFI UA ABRW CZR CCV.CL MU TRI COHU UNH

1
AGTC / Applied Genetic Technologies Corp 10-K 20180630 (Annual Report)

2018-09-11 sec.gov
agtc-10k_20180630.htm UNITED STATES
AGTC

1
Applied Genetic Technologies Corporation (AGTC) CEO Susan Washer on Q4 2018 Results - Earnings Call Transcript

2018-09-10 seekingalpha
Applied Genetic Technologies Corporation (NASDAQ:AGTC) Q4 2018 Results Earnings Conference Call September 10, 2018 4:30 PM ET
AGTC

1
AGTC Announces Financial Results and Business Update for the Fourth Quarter and Fiscal Year Ended June 30, 2018

2018-09-10 globenewswire
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the fourth quarter and fiscal year ended June 30, 2018.
AGTC

51
7 Lucrative Biotech Stocks With Up to 300% Upside

2018-09-06 investorplace - 13
Forget market dynamics. These biotechs are playing to their own tune. According to the Street’s top analysts this can be a very lucrative path. Biotech stocks can spike massively on positive news — be it key trial results or regulatory approvals. Of course, the opposite is also true and the biotech sector can crash just as quickly on unexpected disappointments.
AGTC TOCA GILD OBSV SRNE GLMD MGTX NITE SBPH ABBV ALNY ABBV

3
Histogenics Corporation (HSGX) CEO Adam Gridley on Q2 2018 Results - Earnings Call Transcript

2018-08-13 seekingalpha - 2
Good morning, and welcome to the Histogenics Second Quarter 2018 Financial and Operating Results Conference Call. At this time all participants are in a listen only mode. Later we’ll conduct the question-and-answer session and instructions will follow at that time. [Operator Instructions]
AGTC HSGX

1
AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 15, 2018

2018-08-08 globenewswire
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President and Chief Executive Officer, will present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15th, 2018 at 9:45 am ET in New York.
AGTC

1
AGTC / Applied Genetic Technologies Corp FORM 8-K AMENDMENT NO. 1 (Current Report)

2018-08-02 sec.gov
Form 8-K Amendment No. 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AGTC

1
AGTC / Applied Genetic Technologies Corp 8-K (Current Report)

2018-07-31 sec.gov
8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AGTC

2
Applied Genetic Technologies Corporation: Near-Term Run Up Expected

2018-07-24 seekingalpha - 1
With multiple irons in the fire, a partnership with Biogen and topline 6-month data for its XLRS program coming in Q4, the timing appears right for a run-up.
AGTC VRTX REGN AGN

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 03820J100